2021
Clinical outcomes, Kadish-INSICA staging and therapeutic targeting of somatostatin receptor 2 in olfactory neuroblastoma
Lechner M, Takahashi Y, Turri-Zanoni M, Liu J, Counsell N, Hermsen M, Kaur RP, Zhao T, Ramanathan M, Schartinger VH, Emanuel O, Helman S, Varghese J, Dudas J, Riechelmann H, Sprung S, Haybaeck J, Howard D, Engel NW, Stewart S, Brooks L, Pickles JC, Jacques TS, Fenton TR, Williams L, Vaz FM, O'Flynn P, Stimpson P, Wang S, Hannan SA, Unadkat S, Hughes J, Dwivedi R, Forde CT, Randhawa P, Gane S, Joseph J, Andrews PJ, Royle G, Franchi A, Maragliano R, Battocchio S, Bewicke-Copley H, Pipinikas C, Webster A, Thirlwell C, Ho D, Teschendorff A, Zhu T, Steele CD, Pillay N, Vanhaesebroeck B, Mohyeldin A, Fernandez-Miranda J, Park KW, Le QT, West RB, Saade R, Manes RP, Omay SB, Vining EM, Judson BL, Yarbrough WG, Sansovini M, Silvia N, Grassi I, Bongiovanni A, Capper D, Schüller U, Thavaraj S, Sandison A, Surda P, Hopkins C, Ferrari M, Mattavelli D, Rampinelli V, Facchetti F, Nicolai P, Bossi P, Henriquez OA, Magliocca K, Solares CA, Wise SK, Llorente JL, Patel ZM, Nayak JV, Hwang PH, Lacy PD, Woods R, O'Neill JP, Jay A, Carnell D, Forster MD, Ishii M, London NR, Bell DM, Gallia GL, Castelnuovo P, Severi S, Lund VJ, Hanna EY. Clinical outcomes, Kadish-INSICA staging and therapeutic targeting of somatostatin receptor 2 in olfactory neuroblastoma. European Journal Of Cancer 2021, 162: 221-236. PMID: 34980502, PMCID: PMC9554673, DOI: 10.1016/j.ejca.2021.09.046.Peer-Reviewed Original ResearchConceptsPeptide radionuclide receptor therapyProphylactic neck irradiationDisease-free survivalOlfactory neuroblastomaSomatostatin receptor 2Stable diseaseAdjuvant radiotherapyNeck irradiationOverall survivalReceptor 2Potential efficacyPeptide receptor radionuclide therapyReceptor radionuclide therapyMultivariable survival analysisPertinent clinical dataClinical trial dataKey prognostic markersNodal recurrenceClinical outcomesClinicopathological characteristicsT stagePrognostic valueReceptor therapyDisease stageNeuroblastoma patientsMulticenter Study on Clinical Outcomes of Olfactory Neuroblastoma
Lechner M, Takahashi Y, Hermsen M, Turri-Zanoni M, Schartinger V, Bell D, Helman S, Varghese J, Magliocca K, Dudas J, Riechelmann H, Kaur R, Sprung S, Howard D, Engel N, Zhao T, Liu J, Facchetti F, Maragliano R, Battocchio S, Franchi A, Liu J, Carnell D, Capper D, Schueller U, Forster M, Forde C, Jay A, Manes R, Judson B, Vining E, Woods R, Solares C, O'Neill J, Nicolai P, Surda P, Bossi P, Rampinelli V, Henriquez O, Hopkins C, Thavaraj S, Yarbrough W, London N, Gallia G, Wise S, Llorente J, Castelnuovo P, Hanna E, Lund V. Multicenter Study on Clinical Outcomes of Olfactory Neuroblastoma. Journal Of Neurological Surgery Part B Skull Base 2021, 82: s65-s270. DOI: 10.1055/s-0041-1725285.Peer-Reviewed Original Research
2020
Ideas and Innovations to Improve the Otolaryngology–Head and Neck Surgery Residency Application and Selection Process
Salehi PP, Heiser A, Salehi P, Manes RP, Judson BL, Azizzadeh B, Lee YH. Ideas and Innovations to Improve the Otolaryngology–Head and Neck Surgery Residency Application and Selection Process. Otolaryngology 2020, 164: 1001-1010. PMID: 33076735, DOI: 10.1177/0194599820961989.Peer-Reviewed Original ResearchOutpatient Otolaryngology in the Era of COVID‐19: A Data‐Driven Analysis of Practice Patterns
Kasle DA, Torabi SJ, Savoca EL, Judson BL, Manes RP. Outpatient Otolaryngology in the Era of COVID‐19: A Data‐Driven Analysis of Practice Patterns. Otolaryngology 2020, 163: 138-144. PMID: 32393101, PMCID: PMC7218354, DOI: 10.1177/0194599820928987.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overBetacoronavirusChildChild, PreschoolCoronavirus InfectionsCOVID-19Data AnalysisDisease Transmission, InfectiousFemaleHumansMaleMiddle AgedOtolaryngologistsOtorhinolaryngologic DiseasesOutpatientsPandemicsPneumonia, ViralPractice Patterns, Physicians'Retrospective StudiesSARS-CoV-2TelemedicineUnited StatesYoung AdultConceptsDivision of OtolaryngologyTelehealth visitsOlder adultsHospital policy changesSingle-institution studyCoronavirus disease 2019Quantity of patientsOutpatient otolaryngologyRetrospective reviewAcute carePerson visitsOutpatient appointmentsPractice patternsDisease 2019Week 1Week 3VisitsYoung adultsOtolaryngologyCOVID-19Completion ratesOtolaryngologistsAdultsAssociated increaseTelehealth
2019
Margins in Sinonasal Squamous Cell Carcinoma: Predictors, Outcomes, and the Endoscopic Approach
Torabi SJ, Spock T, Cardoso B, Chao J, Morse E, Manes RP, Judson BL. Margins in Sinonasal Squamous Cell Carcinoma: Predictors, Outcomes, and the Endoscopic Approach. The Laryngoscope 2019, 130: e388-e396. PMID: 31755988, DOI: 10.1002/lary.28315.Peer-Reviewed Original ResearchConceptsSinonasal squamous cell carcinomaHigh-volume facilitiesNational Cancer DatabaseSquamous cell carcinomaPositive marginsOverall survivalSurgical approachMargin statusCell carcinomaEthmoid sinusEndoscopic approachMultivariable binary logistic regressionDecreased overall survivalHigher T stageBinary logistic regressionAdditional therapySelect patientsAdult patientsEndoscopic treatmentMultivariable analysisSurgical managementT stageTherapy administrationDifferentiated tumorsOpen surgeryMulti-modality Treatment and Survival in Sinonasal Minor Salivary Gland Tumors
Torabi SJ, Spock T, Cardoso B, Chao J, Manes RP, Judson BL. Multi-modality Treatment and Survival in Sinonasal Minor Salivary Gland Tumors. Journal Of Neurological Surgery Part B Skull Base 2019, 81: 198-205. PMID: 32206540, PMCID: PMC7082160, DOI: 10.1055/s-0039-1683437.Peer-Reviewed Original ResearchMinor salivary gland tumorsSalivary gland tumorsTriple-modality therapyGland tumorsModality therapyMultimodality treatmentPositive marginsTreatment modalitiesSubset analysisNational Comprehensive Cancer Network guidelinesClinical American Joint CommitteeNational Cancer DatabaseMulti-modality treatmentOnly treatment modalityAmerican Joint CommitteeMost treatment modalitiesAdjuvant chemoradiotherapySurvival benefitSurgical managementNetwork guidelinesCancer DatabaseChemoradiotherapyCommon treatmentSurgeryJoint CommitteeMultimodality Treatment and Survival in Sinonasal Minor Salivary Gland Tumors
Torabi S, Spock T, Cardoso B, Chao J, Manes R, Judson B. Multimodality Treatment and Survival in Sinonasal Minor Salivary Gland Tumors. Journal Of Neurological Surgery Part B Skull Base 2019, 80: s1-s244. DOI: 10.1055/s-0039-1679617.Peer-Reviewed Original Research
2016
Survival Outcomes for Combined Modality Therapy for Sinonasal Undifferentiated Carcinoma
Kuo P, Manes RP, Schwam ZG, Judson BL. Survival Outcomes for Combined Modality Therapy for Sinonasal Undifferentiated Carcinoma. Otolaryngology 2016, 156: 132-136. PMID: 27703092, DOI: 10.1177/0194599816670146.Peer-Reviewed Original ResearchConceptsSinonasal undifferentiated carcinomaCombined modality therapyNational Cancer DatabaseUndifferentiated carcinomaChemoradiotherapy groupModality therapyOverall survivalSurvival outcomesTreatment modalitiesCancer DatabaseSurvival rateAdjuvant chemotherapy groupImproved survival outcomesMultivariate Cox regressionCumulative survival rateKaplan-Meier analysisMulti-institutional studyCases of SNUCAdjuvant chemotherapyChemotherapy groupMultimodality therapyModality treatmentPrognostic factorsCox regressionAggressive malignancy
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply